Evaluating and comparing hospital AI vendors

Lens 1: EHR integration

An AI model is useless if it cannot see live patient data and cannot surface predictions where clinicians already work. Integration is usually the single biggest driver of success or failure.

Key questions:

• Does it read real-time data via HL7 or FHIR (Fast Healthcare Interoperability Resources: modern standards for exchanging health data)? FHIR is the current expectation in 2026.
• Does the alert appear inside the EHR chart, or in a separate app nurses must open? Separate apps get ignored.
• What is the data latency? A sepsis alert that fires 45 minutes late is clinically worthless.

| Vendor | Integration profile | Score |

|--------|--------------------|-------|

| A (native) | Runs inside EHR, real-time, alerts in existing workflow | 5 |

| B (specialist) | FHIR integration, mature but requires interface build | 4 |

| C (startup) | APIAPIApplication Programming Interface: a standardised interface that lets applications communicate and exchange data without knowing each other's internal workings.View full definition → only, alerts in separate dashboard, batch data | 2 |

Lens 2: Clinical validation evidence

Here you separate marketing from medicine. Ask for evidence in this hierarchy, strongest first:

1. Prospective study: tested on live patients going forward, ideally at multiple sites.

2. External validation: tested at hospitals other than where it was built.

3. Retrospective internal: tested only on the vendor's historical data (weakest, and what most vendors show first).

Two metrics matter, and vendors love to hide behind one:

• Sensitivity: of patients who truly develop sepsis, what fraction does the model catch?
• Positive predictive value (PPV): of all the alerts it fires, what fraction are real sepsis?

A model can have high sensitivity and terrible PPV, meaning it catches most cases but drowns staff in false alarms. That is exactly what caused the Epic model backlash and what drives alert fatigue (clinicians tuning out warnings because too many are wrong).

Also ask: was the model FDA-cleared as Software as a Medical Device (SaMD)? In the US, the Food and Drug Administration regulates many diagnostic AI tools. In Europe, the equivalent is CE marking under the Medical Device Regulation (MDR), plus obligations arriving under the EU AI Act, which classifies most clinical decision AI as high-risk. Clearance is not proof of real-world performance, but its absence is a red flag for a diagnostic claim.

| Vendor | Evidence | Score |

|--------|----------|-------|

| A (native) | Retrospective internal only, no external validation | 2 |

| B (specialist) | Prospective multi-site study, FDA-cleared | 5 |

| C (startup) | Retrospective, impressive AUC, no clinical trial | 2 |

Note: AUC (area under the curve) is a common accuracy summary from 0.5 to 1.0. A high AUC on retrospective data does not guarantee bedside value.

Lens 3: Deployment model

How the model lives and updates matters for safety and IT burden.

• On-premise: runs inside hospital servers. More data control, heavier IT load.
• Cloud/SaaS: vendor hosts it. Easier updates, but raises data governancedata governanceData governance is the set of policies, roles, and processes that ensure data is accurate, secure, well-defined, and used responsibly across an organization.View full definition → questions under HIPAA (US) and GDPR (Europe).
• Model drift monitoring: patient populations change, so accuracy decays. Ask who monitors for drift and how often the model is recalibrated. A vendor with no drift plan is selling you a model that quietly degrades.

| Vendor | Deployment | Score |

|--------|-----------|-------|

| A (native) | Cloud, tied to EHR update cycle, no separate drift dashboard | 3 |

| B (specialist) | Hybrid, quarterly recalibration, drift monitoring included | 5 |

| C (startup) | Cloud only, unclear drift process | 2 |

Lens 4: Total cost of ownership (TCO)

Not the license fee. The full cost of running AI over three years. Stay focused on AI-specific costs, not general hospital finance.

TCO components:

• License/subscription (often per bed or per hospital).
• Integration build (interface engineering, FHIR setup).
• IT and data engineering maintenance.
• Clinical change management (training, alert tuning, governance committee time).

That last item is routinely underestimated. Alert tuning and clinician training often cost as much as the software in year one.

#### Worked TCO example (illustrative estimates only)

These are made-up round numbers to show the method, not real vendor prices. Assume a 300-bed hospital, three-year horizon, Vendor B:

• Subscription: $150,000/year x 3 = $450,000
• Integration build (one-time): $120,000
• Ongoing IT maintenance: $40,000/year x 3 = $120,000
• Change management (training, governance, tuning): $90,000 year 1, then $30,000/year x 2 = $150,000

Three-year TCO = 450,000 + 120,000 + 120,000 + 150,000 = $840,000

Now compare against benefit. Suppose the tool contributes to earlier treatment for an estimated 20 additional sepsis patients per year, and each averted deterioration saves an estimated $15,000 in avoided ICU days (again, illustrative):

• Annual estimated benefit: 20 x 15,000 = $300,000
• Three-year benefit: $900,000

Net over three years: 900,000 minus 840,000 = $60,000 positive, with most value coming from clinical outcomes, not headcount savings. The point is not the number. It is that a cheaper license (Vendor C) can lose to a pricier one (Vendor B) once integration, drift monitoring, and change management are included.

Putting the scorecard together

Sum the four lenses (max 20):

| Vendor | Integration | Validation | Deployment | TCO fit | Total |

|--------|:-:|:-:|:-:|:-:|:-:|

| A (native) | 5 | 2 | 3 | 4 | 14 |

| B (specialist) | 4 | 5 | 5 | 3 | 17 |

| C (startup) | 2 | 2 | 2 | 5 | 11 |

Weight the lenses to your context. A hospital with a stretched IT team may weight integration highest, making Vendor A more attractive despite weaker evidence. A large academic center may refuse anything without prospective validation, ruling out A and C regardless of price.

The scorecard does not pick the winner for you. It forces the tradeoffs into the open and stops a slick demo from deciding a clinical safety purchase.

🎬 [VIDEO: "How to Evaluate Clinical AI Tools" - youtube.com - a plain-language walkthrough of validation and integration pitfalls in hospital AI procurement]

A realistic expectation check

Even the best-scoring vendor will not deliver value in isolation. Three sobering realities:

• Prediction is not treatment. An accurate alert only helps if a nurse acts and a rapid-response protocol exists. AI without workflow redesign fails.
• Off-the-shelf accuracy drops on your patients. Always negotiate a silent trial (the model runs without firing alerts) so you can measure real sensitivity and PPV on your population before go-live.
• Governance is permanent. Someone must own monitoring, retraining triggers, and shutdown criteria for the life of the tool.

Key Takeaways

• Score vendors on four lenses: EHR integration, clinical validation evidence, deployment and drift monitoring, and total cost of ownership. Never buy on a demo.
• Demand the strongest validation available: prospective, multi-site, and report both sensitivity and PPV. The Epic Sepsis Model failure came from ignoring real-world PPV.
• TCO is dominated by integration and change management, not the license fee. The cheapest vendor often has the worst true cost.
• Run a silent trial on your own patients before going live, because accuracy nearly always drops outside the vendor's training population.
• Confirm regulatory status (FDA clearance in the US, MDR CE marking and EU AI Act high-risk obligations in Europe), but treat it as a floor, not proof of bedside value.